Adjuvant cytotoxic chemotherapy for early breast cancer: Doubts and decisions

Lancet

Volumn 351, Issue 9114, 1998, Pages 1506-1507

  Dodwell, D J ^a,b  

^a Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; EARLY CANCER; FEMALE; HUMAN; PATIENT INFORMATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK; SHORT SURVEY;

EID: 0032537402     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)11247-8     Document Type: Note

References (13)

1. 1 Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673-82.
2. 2 McNeil C. Chemotherapy benefits nearly all early breast cancer patients. J Natl Cancer Inst 1997; 89: 838-39.
3. 3 Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
4. 4 Slevin M, Stubbs L, Plant H, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. BMJ 1990; 300: 1458-60.
5. 5 Lindley C, Vasa S, Sawyer T, Winer E. Eliciting preferences for adjuvant therapy in patients with early stage breast cancer: trade offs between treatment, cure and survival. Proc Am Soc Clin Oncol 1995; 14: 149 (abstr).
6. 6 Coates A, Simes R. Patients assessment of adjuvant treatment in operable breast cancer. In: Williams C, ed. Introducing new treatments for cancer. Practical ethical and legal problems. New York: Wiley and Sons, 1992: 448-58.
7. 7 Hurny C, Bernhard J, Coates A, et al. Impact of adjuvant therapy on quality of life in women with node-positive breast cancer. Lancet 1996; 347: 1279-84.
8. 8 Gelber R, Cole BF, Goldhirsch A, et al. Adjuvant chemotherapy plus tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996; 347: 1066-71.
9. 9 Mackillop W, Stewart W, Ginsburg A, Stewart S. Cancer patients' perceptions of their disease and its treatment. Br J Cancer 1988; 58: 355-58.
10. 10 Fetting J, Siminoff L, Piantadosi S, et al. Effect of patient's expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: a clinical vignette study. J Clin Oncol 1990; 8: 1476-82.
11. 11 Rajagopal S, Goodman P, Tannock F. Adjuvant chemotherapy for breast cancer: discordance between physicians' perception of benefit and the results of clinical trials. J Clin Oncol 1994; 12: 1296-304.
12. 12 Sainsbury R, Rider L, Smith A, MacAdam A. Does it matter where you live? Treatment variation for breast cancer in Yorkshire. Br J Cancer 1995; 71: 1275-78.
13. 13 Richards M, Ramirez A, Degner L, Fallowfield L, Maher E, Neuberger J. Offering choice of treatment to patients with cancers: a review based on a symposium held at the 10th annual conference of The British Psychosocial Oncology Group, December, 1993. Eur J Cancer 1995; 31A: 112-16.